ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/hepatic/advanced-metastatic
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Upper) / Hepatic - Advanced/metastatic
12
trial(s) found.
NCT06910657
Advanced
Phase 1
Not yet recruiting
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors (
VM-002-101
)
oncolytic virus,undisclosed mechanism
Bladder cancer
Breast cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Head and neck cancer
Hepatocellular carcinoma
Lung cancer
Melanoma
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Sarcoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06533332
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors (
ERX-315-101
)
benzamide,ER alpha-targeting
Breast cancer
Endometrial cancer
Hepatocellular carcinoma
Ovarian cancer
Pancreatic cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06478693
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including Hepatocellular Carcinoma (
MTX-GPC3-303
)
GPC3-targeting lipid-nanoparticle CAR mRNA
GPC3-targeting lipid-nanoparticles
Hepatocellular carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06427941
Advanced
Phase 1
Recruiting
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Selected Advanced or Metastatic Solid Tumors (
BGB-B2033-101
)
anti-GPC3 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastric cancer
Hepatocellular carcinoma
Solid tumour
Squamous non-small-cell lung cancer
Yolk sac tumour
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate
Bladder cancer
Breast cancer
Cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Platinum resistant ovarian cancer
Sarcoma
Small-cell lung cancer
Solid tumour
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05411133
Advanced
Phase 1
Recruiting
A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies (
A001
)
bispecific T-cell engager,CDH17-targeting
Cholangiocarcinoma
Colorectal adenocarcinoma
Gastric cancer
Gastrointestinal cancer
Hepatocellular carcinoma
Oesophageal adenocarcinoma
Pancreatic cancer
NSW
2217 - Kogarah - St George Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05169177
Radonc
Recruiting
Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy (
ROCK-RT
)
radiotherapy
Hepatocellular carcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT04524871
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (
Morpheus-Liver
)
ADG126
Atezolizumab
Bevacizumab
HIF2a inhibitor
NKT2152
PPAR-alpha inhibitor
TPST-1120
Tiragolumab
Tobemstomig
Tocilizumab
anti-CTLA4 monoclonal antibody
anti-IL-6 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,HIF2a-targeting
cancer therapy,IL-6-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PPAR-alpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12624001345572
Curative
Phase 2
Not yet recruiting
DEFINERx050
: A Multicentre, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab (Anti-VEGF Antibody) as Neo-Adjuvant ImmunoTherapy Versus Active Surveillance in Hepatocellular Carcinoma Patients with high Onco-Fetal Characteristics Before Surgical Resection
anti-PD-L1 monoclonal antibody
anti-VEGF monoclonal antibody
Hepatocellular carcinoma
ACTRN12623000798662
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of BOS-342 in Patients with Hepatocellular Carcinoma (
HCC
) and other GPC3-expressing Tumors
bispecific GPC3/4-1BB antibody
Cancer
Hepatocellular carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12621001444875
Radonc
Phase 2
Recruiting
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study) (
The-SOCRATES-HCC-Study
)
Radiotherapy
cancer therapy
Hepatocellular carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (10)
Not yet recruiting (2)
Recruitment Country and State
NSW (8)
VIC (6)
SA (5)
QLD (4)
WA (2)
NZ (2)
Phase
Phase 1 (7)
Phase 1 / Phase 2 (2)
Phase 2 (2)
Trial Type
Advanced (9)
Radonc (2)
Curative (1)
Cancer Therapy Class
GPC3
25%
PD-1/PD-L1
25%
PD-1
17%
PD-L1
17%
VEGF
17%
ER alpha
8%
oestrogen axis
8%
B7H3
8%
MET
8%
CDH17
8%
CTLA4
8%
HIF2a
8%
IL-6
8%
LAG3
8%
PPAR-alpha
8%
TIGIT
8%
4-1BB
8%
Facility
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
3004 - Melbourne, Southbank - Alfred Health (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
5042 - Bedford Park - Flinders Medical Centre (2)
2109 - North Ryde - Macquarie University Hospital (1)
4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
2217 - Kogarah - St George Private Hospital (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
Cancer Type
Cancer
Gastrointestinal cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Solid tumour
Upper gastrointestinal cancer
Gastroesophageal cancer
Pancreatic cancer
Pancreatobiliary cancer
Thoracic cancer
Breast cancer
Gastric cancer
Gynaecological cancer
Ovarian cancer
Colorectal cancer
Head and neck cancer
Lower gastrointestinal cancer
Lung cancer
Male genital cancers
Oesophageal cancer
Respiratory tract cancer
Urogenital cancer
Bladder cancer
Cervical cancer
Clear cell renal cell carcinoma
HPV-related cancer
HPV16-positive cancer
Kidney cancer
Melanoma
Prostate cancer
Sarcoma
Viral-related cancer
Endometrial cancer
Non-small cell lung cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Biliary tract cancer
Germ cell tumour
Non-seminoma
Squamous non-small-cell lung cancer
Testicular cancer
Yolk sac tumour
Carcinoma
Castrate-resistant prostate cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Neuroendocrine carcinoma
Ovarian adenocarcinoma
Ovarian serous carcinoma
Platinum resistant ovarian cancer
Prostate adenocarcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Breast adenocarcinoma
Exocrine pancreatic cancer
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
Cholangiocarcinoma
Colorectal adenocarcinoma
Oesophageal adenocarcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy